CSIMarket
 


Aldeyra Therapeutics Inc   (ALDX)
Other Ticker:  
 

Aldeyra Therapeutics Inc 's Working Capital Ratio

ALDX's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2023, Working Capital Ratio fell to 6.83 below Aldeyra Therapeutics Inc average.

Within Major Pharmaceutical Preparations industry 178 other companies have achieved higher Working Capital Ratio than Aldeyra Therapeutics Inc in third quarter 2023. While Working Capital Ratio total ranking in the third quarter 2023 has deteriorated compared to the prior quarter from 494 to 639.

Explain Working Capital Ratio
How much in Current Assets ALDX´s has?
What is the value of ALDX´s Current Liabilities?


ALDX Working Capital Ratio (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities Change -10.24 % -3.28 % -3.28 % 28.36 % 101.06 %
Y / Y Current Assets Change -22.31 % -22.55 % -24.44 % -22.23 % -23.22 %
Working Capital Ratio MRQ 6.83 10.05 10.62 11.98 7.89
ALDX's Total Ranking # 639 # 494 # 384 # 398 # 749
Seq. Current Liabilities Change 39.26 % -2.16 % 4.67 % -37.06 % 50.06 %
Seq. Current Assets Change -5.32 % -7.46 % -7.18 % -4.46 % -5.61 %



Working Capital Ratio third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 179
Healthcare Sector # 303
Overall Market # 639


Working Capital Ratio Statistics
High Average Low
35.15 12.68 3.12
(Jun 30 2021)   (Mar 31 2014)




Financial Statements
Aldeyra Therapeutics Inc 's Current Liabilities $ 22 Millions Visit ALDX's Balance sheet
Aldeyra Therapeutics Inc 's Current Assets $ 147 Millions Visit ALDX's Balance sheet
Source of ALDX's Sales Visit ALDX's Sales by Geography


Cumulative Aldeyra Therapeutics Inc 's Working Capital Ratio

ALDX's Working Capital Ratio for the trailling 12 Months

ALDX Working Capital Ratio

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities TTM Growth -10.24 % -3.28 % -3.28 % 28.36 % 101.06 %
Y / Y Current Assets TTM Growth -22.31 % -22.55 % -24.44 % -22.23 % -23.22 %
Working Capital Ratio TTM 9.59 9.86 10.42 11.1 12.41
Total Ranking TTM # 462 # 3902 # 3857 # 3768 # 304
Seq. Current Liabilities TTM Growth 39.26 % -2.16 % 4.67 % -37.06 % 50.06 %
Seq. Current Assets TTM Growth -5.32 % -7.46 % -7.18 % -4.46 % -5.61 %


On the trailing twelve months basis In spite of the year on year decrease in ALDX's Current Liabilities to $21.55 millions, cumulative Working Capital Ratio to 9.59 below the ALDX average Working Capital Ratio.
Working Capital Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 176 other companies have achieved higher Working Capital Ratio than Aldeyra Therapeutics Inc . While Working Capital Ratio overall ranking has improved so far to 462, from total ranking during the twelve months ending second quarter 2023 at 3902.

Explain Working Capital Ratio
How much in Current Assets ALDX´s has?
What is the value of ALDX´s Current Liabilities?

TTM Working Capital Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 177
Healthcare Sector # 298
Within the Market # 462


trailing twelve months Working Capital Ratio Statistics
High Average Low
20.91 11.76 7.63
(Dec 31 2021)   (Dec 31 2019)




Companies with similar Working Capital Ratio in the quarter ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Working Capital RatioSep 30 2023 MRQ Current AssetsSep 30 2023 MRQ Current Liabilities
Nextcure Inc   18.72 $ 122.684  Millions$ 6.552  Millions
Fulcrum Therapeutics Inc   18.65 $ 262.490  Millions$ 14.075  Millions
Compass Pathways Plc  18.55 $ 284.806  Millions$ 15.350  Millions
Edgewise Therapeutics inc   18.23 $ 297.921  Millions$ 16.338  Millions
Keros Therapeutics Inc   18.23 $ 304.435  Millions$ 16.701  Millions
89bio Inc   18.23 $ 459.526  Millions$ 25.212  Millions
Trevi Therapeutics Inc   18.16 $ 93.953  Millions$ 5.173  Millions
Kura Oncology Inc   17.80 $ 459.917  Millions$ 25.843  Millions
Olema Pharmaceuticals inc   17.66 $ 282.008  Millions$ 15.966  Millions
Briacell Therapeutics Corp   17.59 $ 18.408  Millions$ 1.047  Millions
Cadrenal Therapeutics Inc   17.23 $ 9.278  Millions$ 0.539  Millions
Zomedica Corp   17.12 $ 115.394  Millions$ 6.740  Millions
Day One Biopharmaceuticals Inc   16.89 $ 413.291  Millions$ 24.475  Millions
Lyell Immunopharma Inc   16.74 $ 586.854  Millions$ 35.064  Millions
Vanda Pharmaceuticals Inc   16.46 $ 536.572  Millions$ 32.595  Millions
Inozyme Pharma Inc   16.36 $ 200.856  Millions$ 12.275  Millions
Ligand Pharmaceuticals Incorporated  16.15 $ 253.994  Millions$ 15.727  Millions
Agios Pharmaceuticals Inc   16.10 $ 704.352  Millions$ 43.761  Millions
Acrivon Therapeutics Inc   15.54 $ 144.492  Millions$ 9.299  Millions
Dynavax Technologies Corporation  15.40 $ 835.666  Millions$ 54.264  Millions
Larimar Therapeutics Inc   15.02 $ 98.480  Millions$ 6.558  Millions
Dianthus Therapeutics Inc   14.64 $ 191.453  Millions$ 13.079  Millions
Artelo Biosciences Inc   14.58 $ 13.428  Millions$ 0.921  Millions
Nuvalent Inc   14.42 $ 419.773  Millions$ 29.103  Millions
Verve Therapeutics Inc   14.41 $ 498.261  Millions$ 34.575  Millions
Minerva Neurosciences Inc   14.40 $ 48.225  Millions$ 3.350  Millions
Prelude Therapeutics Inc  14.31 $ 234.916  Millions$ 16.418  Millions
Rezolute Inc   14.27 $ 102.645  Millions$ 7.195  Millions
Crinetics Pharmaceuticals Inc   14.23 $ 575.760  Millions$ 40.463  Millions
Rallybio Corporation  14.08 $ 132.422  Millions$ 9.402  Millions

Date modified: 2023-11-04T19:52:30+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com